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Antibodies that stimulate the immune system by targeting inhibitory T cell receptors were successfully introduced
into oncological practice and are capable to overcome tumor-induced immune evasion. In particular, targeting of
the inhibitory receptors CTLA-4 and PD-1 or its ligand PD-L1 have been shown to be beneficial for patients with
melanoma, renal cell cancer, non-small cell lung cancer and a growing list of other cancers with impressive response
rates. Here, we report a severe, potentially life-threatening side effect of anti-PD-1 immunotherapy with pembrolizumab,
which has not been previously described in the literature. A 73-year-old woman with metastatic uveal melanoma
treated with pembrolizumab in third line developed severe heart failure due to pembrolizumab-mediated autoimmune
myocarditis. Echocardiographic studies revealed a severely impaired left ventricular function with dyssynchrony. All tests
for cardiotropic viruses were negative and histological analysis of a myocardial biopsy showed lymphocytic infiltration
with a predominance of CD8 positive cells and a reduction of FOXP3 positive regulatory T cells. After initiation of
corticosteroids and guideline-conform heart failure therapy, the symptoms rapidly improved and the left ventricular
function recovered. While autoimmune myocarditis is a documented side effect of other checkpoint inhibitors, as for
example ipilimumab and in one case with anti-PD-L1 antibody, it is not described for anti-PD-1-antibodies like pembrolizumab
or nivolumab. As the FDA recently approved both pembrolizumab and nivolumab for melanoma progressing after
anti-CTLA-4 treatment with ipilimumab, more patients will soon receive anti-PD-1 therapy. Thus, it is important to be
aware of such rare, but severe immune-related adverse events.
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The field of cancer immunotherapy is currently moving
forward at an accelerated pace. Though early clinical
trials have yielded mixed results with ambiguous clinical
benefit [1], cancer immunotherapy is now attracting
increasing attention as viable therapeutic option, both in
melanoma and in other malignancies [2]. In particular,
recent therapeutic efforts targeting inhibitory receptors on
T cells to overcome tumor-induced immune dysfunction
has been successfully introduced into oncological practice.
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unless otherwise stated.antibodies has been pioneered by the antibody ipilimumab
(Yervoy®), which inhibits CTLA-4 and has demonstrated
survival benefit in two randomized landmark trials in
melanoma [3,4]. Capitalizing on this success, research on
clinically relevant T cell checkpoint inhibition has been
boosted. Early clinical trials have demonstrated meaningful
response rates, sustained clinical benefits with exceptional
survival rates and good tolerability of next-generation
checkpoint inhibitors, including PD-1 and PD-L1 inhibi-
tors across multiple cancer types [5-10]. Exciting perspec-
tives include the concurrent blockade of different
immunologic (non-redundant) checkpoints. The feasibility
of this approach has recently been demonstrated in melan-
oma using combined CTLA-4 and PD-1 inhibition [11].
Inhibition of immune checkpoints induces side effects
defined as “immune-related adverse events” (irAEs) [12].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Computed tomography at initiation of pembrolizumab.
Computed tomography scan of the liver before treatment with
pembrolizumab was initiated after progression with the treatment
of ipilimumab.
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these toxicities. Such irAEs often affect the skin, the in-
testinal mucosa or endocrine organs. Here, we report a
case of autoimmune myocarditis with consecutive heart
failure after treatment targeting PD-1.
Case presentation
A 73-year-old woman with metastatic uveal melanoma
presented for a clinical examination and laboratory control
under third-line therapy with pembrolizumab (MK-3475)
in our oncological outpatient department. She suffered
from progressive, severe dyspnea. Fourteen years earlier, a
malignant uveal melanoma of her left eye was diagnosed
and treated by ablative proton therapy. In February 2013,
a relapse with hepatic metastases was diagnosed. No
BRAF or NRAS mutations were found in the liver biopsy
in accordance with low frequency of such mutations in
uveal melanoma. The patient had no prior history of
autoimmune or allergic disease. The hepatic lesions
showed progressive disease after treatment with two cy-
cles of dacarbazine, and, subsequently, four cycles with
the anti-CTLA-4 antibody ipilimumab. Importantly, the
latter therapy was tolerated without any adverse events.
To improve local control, selective internal radiation
therapy (SIRT) of the largest liver lesions was performed
in December 2013. However, computed tomography
6 months later showed new bone, pulmonary, mesenterial
and peritoneal metastasis (Figure 1). Palliative radiation
therapy of symptomatic, lytic bone lesions was performed
and denosumab monthly was started. Moreover, anti-PD1
therapy with pembrolizumab was initiated one month
later at a dose of 2 mg per kilogram body weight every
third week, which led to stabilization of the disease after
8 weeks. The patient had no history of cardiac disease.
When she presented with progressive dyspnea (New York
Heart Association Stage (NYHA) IV), she had received five
cycles of pembrolizumab. Her prior medical history was
free of any heart diseases or corresponding symptoms. Clin-
ical examination now revealed congested neck veins, bilat-
eral rales and lower leg edema. The electrocardiogram
(ECG) showed a tachycardiac sinus rhythm with ventricular
bigemy (Figure 2). Brain natriuretic peptide (BNP) and
high-sensitivity troponin T (hs-TnT) levels were elevated
(928 ng/L and 0.63 μg/L, respectively). Thyroid stimulating
hormone levels were within normal range (2.65 mlU/l). A
pulmonary embolism or pneumonitis was excluded by
computed tomography. The transthoracic echocardiog-
raphy revealed a severely impaired left ventricular ejection
fraction (LVEF) of 30% with marked ventricular dyssyn-
chrony (Movie Clip, Additional files 1-3). Taken together,
the clinical presentation corresponded to acute heart failure.
The cardiac MRI did not show any signs consistent with
an acute myocarditis or myocardial ischemia. Confronted
with an unclear acute heart failure under immunotherapy,we performed a myocardial biopsy, which eventually con-
firmed the diagnosis of a lymphocytic myocarditis. An in-
filtration predominantly CD8 positive T cells was noted
(Figure 3). Only a few FOXP3 positive, regulatory T cells
were found showing signs of apoptosis (Figure 3). Sero-
logical and in situ analyses for cardiotropic viruses were
negative. Thus, the diagnosis of immune-mediated myo-
carditis as irAE under pembrolizumab treatment was
rendered.
We started a therapy with an AT2-receptor blocker
(candesartan), a beta-blocker (bisoprolol), aldosterone-
antagonist (spironolactone) and diuretics (torasemid) ac-
cording to ACC/AHA guidelines as well as prednisone
2 mg per kilogram body weight. Within two weeks, our
patient showed a significant symptomatic recovery
(NYHA II). This was in accordance with a normalization
of the ECG (Figure 2) and echocardiographic improve-
ment of left ventricular function (mildly reduced LVEF,
Figure 2 Electrocardiograms – At presentation and during follow-up. The electrocardiograms at admission, after 10 and 19 days of treatment
are presented.
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decreased (154 ng/L and 0.075 μg/L, respectively). The
patient could be discharged and anti-PD1 therapy was
halted. No other specific anti-tumor therapy was initi-
ated at the time.
Discussion
On September 4, 2014, the FDA granted accelerated
approval of pembrolizumab (KEYTRUDA®) for the
treatment of patients with unresectable or metastatic
melanoma and disease progression following ipilimumab
after the analysis of an expansion cohort of the
KEYNOTE-001 trial of 173 patients [6]. The 2 mg and
10 mg per kilogram body weight regimens every 3 weeks
showed similar response rates. Drug-related adverse
events of any grade occurred in 82% and only 12% had
grade 3 or 4 adverse events [6]. Grade 3 or 4 side effectsdue to immune stimulation or irAEs were only noted
in 3 patients and included autoimmune hepatitis, maculo-
papular rash and pancreatitis [6]. In earlier studies of pem-
brolizumab, 4% of patients had pneumonitis, 1% grade 3
aminotransferase elevation, 8% hypothyroidism, 2% poten-
tially autoimmune-mediated renal failure and one patient
had autoimmune adrenalitis and hyperthyroidism [8].
Diarrhea developed in 20% of patients, but was usually
mild and could be controlled without glucocorticoids [8].
Toxicities were less frequent in patients receiving 2 mg
per kilogram body weight every 3 weeks compared to
10 mg every two or three weeks [8]. The toxicity profile
and frequency of irAEs under pembrolizumab alone com-
pared favorable to anti-CTLA-4 treatment with ipilimu-
mab alone or in combination with anti-PD-1 therapy with
nivolumab [11,12]. Similarly, pneumonitis, a potentially
life-threatening complication, was noted less frequently
Figure 3 Histological analysis of endomyocardial biopsy. (a) Hematoxylin and eosin staining of the myocardial biopsy with focal mononuclear
infiltrates. (b) Immunohistochemical analysis of CD68 macrophages. (c) Staining for CD8 positive T cells (d) and FOXP3 positive cells within the myocardium
of the patient.
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alone [10], although the tumor type likely plays a role in
the toxicity profile. Future studies in other tumor types
and combinations of immunostimulatory therapies that
include pembrolizumab will certainly require careful mon-
itoring and dose escalation schemes to avoid severe irAEs.
Temporary or definitive discontinuation of immunostimu-
latory treatment and temporary immunosuppression can
be an effective treatment in most cases and safety manage-
ment guidelines are implemented in clinical trials and
should also be used for patients treated outside trials [7].
There is no prior report on perimyocarditis or endo-
carditis after treatment with pembrolizumab [6,8]. While
a similar spectrum of toxicities was observed with anti-
PD-1 antibody nivolumab [5,7] and anti-PD-L1 antibody
[9,13-15], only one case of myocarditis was reported in a
phase one trial testing anti-PD-L1 antibody [9]. Myo-
carditis of non-infectious cause was previously de-
scribed with anti-CTLA-4 treatment [3]. Histological
analysis of autoimmune lesions and tumors after treat-
ment with immune checkpoint inhibitors usually
shows infiltration of effector CD8 T cells and reduction
of regulatory FOXP3 positive T cells similarly as seen
in the analysis of the myocardial biopsy in our patient
[16] (Figure 3). Interestingly, various tissue-specific
autoimmune conditions are observed in mice deficientfor PD1 (Pdcd1−/−) [17]. These mice, particularly with
a Balb/c background, die of heart disease, which is
similar to human dilated cardiomyopathy. There is
almost no inflammation in the heart of these mice and
subsequent analyses revealed that auto-antibodies
against cardiac troponin I are responsible for the dis-
ease [18]. In mice that are genetically predisposed to
systemic autoimmunity, PD1 deficiency results in fatal
myocarditis by 10 weeks of age that is reminiscent of
Ctla4−/− mice [19]. Massive infiltration of both CD4
positive and CD8 positive T cells and myeloid cells was
found in hearts of those mice concomitant with the pro-
duction of high-titer auto-antibodies against cardiac my-
osin. Subsequent experimental work clearly confirmed the
important role for PD-1 in protecting the heart from T
cell-mediated damage [20]. PD-1–deficient T lympho-
cytes caused enhanced disease with increased cytotoxic
activity and inflammatory infiltrate.
Differential diagnosis of lymphocytic myocarditis and
dilated cardiomyopathy includes infections with cardio-
tropic viruses. Among viral causes, enteroviruses and
adenoviruses are historically common causes, but more
recently, parvovirus B19, the recent H1N1 influenza
pandemic, and human herpes virus 6 have become more
prominent [21]. Although it carries some inevitable limi-
tations, the endomyocardial biopsy remains the gold
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to the Dallas criteria, myocarditis is defined by lympho-
cytic infiltrates with or without myocyte necrosis.
Lately, these criteria were challenged due to their limi-
tations, including low sensitivity and high interob-
server variability in interpretation of biopsy samples
[22,23]. Therefore, advances in immunohistochemistry
and PCR analyses of the endomyocardial specimens
improved diagnostic accuracy for myocarditis [22,23].
In the presented case, we performed extensive diagnos-
tics and excluded a viral cause for myocarditis. It is
therefore very likely that the myocarditis of the patient
was a result of immune stimulation due to PD-1 block-
ade with pembrolizumab.
Conclusion
We report here an autoimmune myocarditis as a side ef-
fect of an anti-PD-1-antibody, completely resolving after
a therapy with high-dose corticosteroids. To our know-
ledge, it is the first time an autoimmune myocarditis
under pembrolizumab treatment is reported. It is a doc-
umented side effect of other checkpoint-inhibitors, as
for example ipilimumab and in one case with anti-PD-
L1 antibody, but not in anti-PD-1-antibodies like pem-
brolizumab or nivolumab. Our report should raise
awareness for de novo cardial dysfunction in patients
under PD-1 blockade. Approval of pembrolizumab and
nivolumab by the FDA for the treatment of melanoma
will lead to the use of these antibodies in a broader
patient population with more concomitant diseases.
Further ongoing studies and experience with patients
outside of trials will provide more information about
such rare side effects.
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